Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
NCT ID NCT07660094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a combination of an injected virus therapy (CAN-2409) and an immunotherapy drug (pembrolizumab) can help people with stage IV non-squamous non-small cell lung cancer live longer than standard chemotherapy. The virus is designed to kill tumor cells and trigger the immune system to attack the cancer. Participants must have a tumor in the chest that can be injected, and their cancer must have worsened despite prior treatment with pembrolizumab-based therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Aglatimagene besadenovec (CAN-2409) plus valacyclovir and pembrolizumab
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced non-squamous lung cancer whose disease has progressed despite immunotherapy.
- What could go wrong
- This is an early-phase trial, and the experimental therapy involves multiple injections into tumors, which may cause side effects. It is not yet proven to be better than standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- New drug duo aims to tackle Hard-to-Treat cancers
- New drug IDP-001 takes on advanced cancers in early trial